A provider's guide to helping patients afford Apixaban. Covers manufacturer programs, generic options, discount cards, and cost conversation strategies.
Apixaban (brand name Eliquis) is one of the most effective direct oral anticoagulants available — but for years, its cost has been a significant barrier to adherence. Even with the introduction of generic Apixaban in late 2024, many patients still face confusion about pricing, coverage gaps, and which savings options apply to their situation.
As a prescriber, you're often the first person patients turn to when they can't afford their medication. This guide provides a practical framework for helping patients navigate Apixaban costs, including manufacturer programs, discount tools, generic substitution strategies, and how to integrate cost conversations into your clinical workflow.
Understanding the price landscape helps you guide patients more effectively:
The key takeaway: most patients can now afford Apixaban, but many don't know about their options unless someone tells them.
The brand manufacturer offers a co-pay savings card for commercially insured patients:
This card is most useful for commercially insured patients who are still on brand Eliquis and face high copays. For patients who have been switched to generic, the card typically doesn't apply.
For uninsured or underinsured patients who cannot afford their medication:
Pfizer's patient assistance portal connects eligible patients to:
Your office staff can help patients initiate applications. Many of these programs accept fax-based enrollment, and approval timelines are typically 2-4 weeks.
For patients paying cash or facing high copays on generic Apixaban, discount card platforms can provide meaningful savings:
These tools are free, require no enrollment, and work at most major pharmacy chains. Consider printing a GoodRx or SingleCare card for Apixaban and keeping copies in your exam rooms or at checkout.
Coupon card prices and insurance copays are separate. Some patients will find that their insurance copay for generic Apixaban is actually higher than the cash price with a discount card. Encourage patients to ask their pharmacist to compare both options at the counter.
Multiple generic manufacturers began producing Apixaban in late 2024 following patent litigation settlements with Bristol-Myers Squibb and Pfizer. Key points for prescribers:
If you've been writing "Eliquis" on prescriptions, ensure your prescribing reflects willingness to allow generic substitution (i.e., do not check "dispense as written" unless clinically necessary). This single step can save patients hundreds of dollars per month.
If cost remains prohibitive even with generic Apixaban, consider therapeutic alternatives based on the clinical scenario:
For a detailed comparison, see our clinical guide: Alternatives to Apixaban.
Many providers avoid cost conversations due to time constraints or discomfort. Here are practical strategies to integrate them efficiently:
A simple question — "Are you having any trouble affording your Apixaban?" — can uncover adherence issues before they lead to missed doses and adverse events. Patients often won't volunteer this information unless asked directly.
Unless there's a specific clinical reason for brand-name Eliquis, prescribe Apixaban generically and ensure "substitution permitted" is selected in your EHR. Review existing patients on brand Eliquis who might benefit from switching to generic.
Have your staff maintain a current list of:
Establish relationships with local pharmacies that consistently stock generic Apixaban at competitive prices. Some independent pharmacies offer better cash pricing than chain pharmacies. Knowing which pharmacies to recommend saves patients time and money.
Document cost conversations and interventions in the patient's chart. This helps other providers on the care team understand the patient's financial situation and avoids redundant conversations. It also creates a record that supports prior authorization appeals if needed.
If your practice has social workers, care coordinators, or patient navigators, involve them in connecting patients with assistance programs. They can handle the enrollment paperwork and follow-up that you may not have time for during a clinical visit.
Cost isn't the only barrier — availability matters too. Some patients find that their pharmacy is out of stock, especially when switching between generic manufacturers. A few resources to share with your patients and staff:
For a comprehensive overview of the current supply situation, see our provider-focused article: Apixaban Shortage: What Providers Need to Know.
The arrival of generic Apixaban has been transformative for affordability, but patients still need guidance to access the best price. By defaulting to generic prescribing, keeping savings resources handy, and normalizing cost conversations in clinical encounters, you can significantly improve adherence and outcomes for your anticoagulant patients.
The tools exist — manufacturer programs, discount cards, patient assistance, and generic alternatives. The challenge is connecting patients to the right resource at the right time. That's where your role as a provider is irreplaceable.
Visit Medfinder for Providers to see how we can help your practice support patients in finding and affording their medications.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
